Chief Executive Officer, RxCelerate Ltd
In April 2013, Jill Reckless co-founded RxCelerate Ltd with David Grainger, an out-sourcing drug discovery and development platform, which specialises in providing complete preclinical and clinical development programmes to the pharmaceutical and biotech sector. RxCelerate focuses on delivering the highest quality cutting edge research and development capabilities, at the same time as cutting costs and timelines for client companies of all sizes.
As Chief Executive Officer, Jill provides extensive leadership within the business (currently 38 employees). She offers an insightful strategic vision and manages business development globally. As Chief Scientific Officer, Jill also oversees drug development programmes and clinical trials that are carried out for external clients.
In April 2018, RxCelerate acquired Cambridge based specialist Contract Research Organisation Total Scientific Ltd. In May 2018, RxCelerate further acquired The Cambridge Partnership, which specialises in providing accountancy, company secretarial and IP management to assist in supporting small biotech companies.
Previously, Jill was an academic in the Department of Medicine at the University of Cambridge until December 2011, having completed her PhD at the National Heart and Lung Institute in London. Her research career has been involved in the development of novel anti-inflammatory drugs by investigating the molecular mechanisms responsible for chronic inflammation and disease, both within the University as a Senior Research Associate and as part of Funxional Therapeutics and Epsilon-3 Bio as Head of Biology.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557